Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NFIL3 Biologics Sequence Review Report 2026: Nuclear factor interleukin-3-regulated protein Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NFIL3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
NCOA7 Biologics Sequence Review Report 2026: Nuclear receptor coactivator 7 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NCOA7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
NCOA6 Biologics Sequence Review Report 2026: Nuclear receptor coactivator 6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NCOA6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
NCOA3 Biologics Sequence Review Report 2026: Nuclear receptor coactivator 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NCOA3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
NCOA1 Biologics Sequence Review Report 2026: Nuclear receptor coactivator 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NCOA1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
NCAM2 Biologics Sequence Review Report 2026: Neural cell adhesion molecule 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NCAM2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MYDGF Biologics Sequence Review Report 2026: Myeloid-derived growth factor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MYDGF sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MST1 Biologics Sequence Review Report 2026: Hepatocyte growth factor-like protein Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MST1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MRGPRD Biologics Sequence Review Report 2026: Mas-related G protein-coupled receptor member D Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MRGPRD sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MNDA Biologics Sequence Review Report 2026: Myeloid cell nuclear differentiation antigen Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MNDA sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MLANA Biologics Sequence Review Report 2026: Melanoma antigen recognized by T-cells 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MLANA sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MEGF9 Biologics Sequence Review Report 2026: Multiple epidermal growth factor-like domains protein 9 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MEGF9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
211
212
213
214
215
>>
2260
>